-+ 0.00%
-+ 0.00%
-+ 0.00%

U.S. Patent And Trademark Offices Issues Notice Of Allownace For Hoth Therapeutics' HT-KIT Therapeutic

Benzinga·05/26/2026 12:33:27
Listen to the news

Allowed Claims Cover Composition-of-Matter and Methods Targeting MS4A6A Pre-mRNA Splicing to Reduce Surface Expression of the High-Affinity IgE Receptor (FcεRI); Strengthens Intellectual Property Foundation Underlying the HT-KIT Mast Cell Program